Marine embryonic stem cells, cells derived therefrom, and methods of preparing same

A method for culturing marine embryonic stem cells in serum-free suspension systems maintains pluripotency and differentiates them into adipocytes and myocytes, addressing scalability and ethical issues in marine stem cell cultivation.

WO2026234670A1PCT designated stage Publication Date: 2026-11-12MEALIWAYS TECHNOLOGIES LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IL2026/050378
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-05
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing methods for cultivating marine embryonic stem cells are limited by scalability and require serum-containing environments, posing ethical, cost, and reproducibility challenges, and adapting suspension culture systems for marine cells faces additional hurdles due to distinct cellular adhesion properties and nutrient requirements.

Method used

A method for maintaining pluripotency of marine embryonic stem cells in a culture using a cell culture medium with basal medium and serum or serum replacement, followed by 2D and 3D culturing, and differentiating these cells into adipocytes or myocytes using specific differentiation agents like insulin and retinoic acid.

Benefits of technology

Enables reliable and scalable production of marine-derived cultured meat products by maintaining pluripotency and differentiating stem cells into target cell types, such as adipocytes and myocytes, while avoiding serum-dependent systems.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IL2026050378_12112026_PF_FP_ABST
    Figure IL2026050378_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention is directed to a method for maintaining pluripotency of a marine embryonic stem cell in a culture, including: (a) isolating an embryonic stem cell from an embryo of a marine organism; and culturing the isolated embryonic stem cell from step (a) in a cell culture medium comprising: (i) a basal medium; and (ii) serum or a serum replacement, wherein the culturing is in 2D followed by culturing in 3D.
Need to check novelty before this filing date? Find Prior Art

Description

MARINE EMBRYONIC STEM CELLS, CELLS DERIVED THEREFROM, AND METHODS OF PREPARING SAME CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority of Israel Patent Application No.320687, entitled “MARINE EMBRYONIC STEM CELLS, CELLS DERIVED THEREFROM, AND METHODS OF PREPARING SAME”, filed May 5, 2025, the contents of which are incorporated herein by reference in their entirety.FIELD OF INVENTION

[0002] The present invention is directed to, inter alia, compositions of fish derived cells, and methods of producing the same.BACKGROUND OF THE INVENTION

[0003] Efforts to scale up embryonic stem cells growth for mass production using suspension cultures have shown promise in various species but remain scarce for marine organisms. Traditional methods for marine embryonic stem cells rely on adherent culture systems, which are inherently limited in scalability and require extensive optimization to maintain cells in a stable, pluripotent state over multiple passages. These methods often depend on serum-containing environments that pose ethical, cost, and reproducibility challenges.

[0004] Attempts to adapt suspension culture systems for embryonic stem cells have been primarily confined to mammalian models, where serum-free and defined media approaches are better established. However, marine embryonic stem cells face additional hurdles, including distinct cellular adhesion properties and nutrient requirements, which further complicate adaptation to suspension cultures.

[0005] There is still a great need for innovative approaches to cultivate marine-derived cells in scalable, serum-free suspension systems.SUMMARY OF THE INVENTION

[0006] The present invention, in some embodiments, provides a method for reliable and scalable production of marine-derived cultured meat products.

[0007] According to the first aspect, there is provided a method for maintaining pluripotency of a marine embryonic stem cell in a culture, the method comprising: (a) isolating an embryonic stem cell from an embryo of a marine organism; and (b) culturing the isolated embryonic stem cell from step (a) in a cell culture medium comprising: (i) a basal medium; and (ii) serum or a serum replacement, wherein culturing is culturing in 2D followed by culturing in 3D, thereby, maintaining pluripotency of the marine embryonic stem cell in a culture.

[0008] According to another aspect, there is provided a method for differentiating a marine embryonic pluripotent stem cell in a culture into an adipocyte cell, the method comprising contacting the marine embryonic pluripotent stem cell with an effective amount of a differentiation agent comprising: insulin, oleic acid, or both.

[0009] According to another aspect, there is provided a method for differentiating a marine embryonic pluripotent stem cell in a culture into a myocyte cell, the method comprising contacting the marine embryonic pluripotent stem cell with an effective amount of a differentiation agent comprising retinoic acid.

[0010] According to another aspect, there is provided a composition comprising a suspension of fish embryonic stem cells, wherein the fish stem cells are not in the form of embryoid body.

[0011] According to another aspect, there is provided a composition comprising a suspension of fish adipocyte cells, wherein the fish adipocyte cells are present in the suspension in the form of aggregates, solitary cells, or a combination thereof.

[0012] According to another aspect, there is provided a composition comprising a suspension of fish myocyte cells, wherein the fish myocyte cells are present in the suspension in the form of: solitary cells, aggregates, or a combination thereof.

[0013] In some embodiments, the cell culture medium further comprises any one of: basic fibroblast growth factor (bFGF), IL-6 / IL-6Ra chimera, epidermal growth factor (EGF), a non-essential amino acid or a plurality thereof, an antibiotic agent, and any combination thereof.

[0014] In some embodiments, the basal medium is any one of: L-15, DMEM, F12, and a combination thereof.

[0015] In some embodiments, the culturing in 2D is for a period of between 50 and 200 days.

[0016] In some embodiments, the culturing in 3D is for a period of between 1 and 60 days.

[0017] In some embodiments, the culturing in 3D is solid support-free culturing.

[0018] In some embodiments, the cells cultured in 3D are in the form of cell aggregates, single solitary cells, or a combination thereof.

[0019] In some embodiments, the method further comprises a step after step (b) comprising differentiating the cultured isolated embryonic cell in a pluripotent state, into a target cell type.

[0020] In some embodiments, the target cell type is an adipocyte, a myocyte, or a combination thereof.

[0021] In some embodiments, the differentiating comprises contacting the cultured isolated embryonic cell in a pluripotent state with an effective amount of a differentiation agent comprising: insulin, oleic acid, retinoic acid, or any combination thereof.

[0022] In some embodiments, the target cell is an adipocyte, and wherein the differentiation agent is an adipogenesis inducing agent comprising: insulin, oleic acid, or both.

[0023] In some embodiments, the target adipocyte comprises omega 3 fatty acid in an increased amount compared to a control cell.

[0024] In some embodiments, the differentiating further comprises subjecting the contacted cultured isolated embryonic cell to a temperature ranging between any one of: 18 °C and 26 °C, and 34 °C and 40 °C.

[0025] In some embodiments, the target cell is a myocyte, and wherein the differentiation agent is a myogenesis inducing agent comprising retinoic acid.

[0026] In some embodiments, the marine organism is a fish.

[0027] In some embodiments, the serum is fetal bovine serum, fish serum, or a combination thereof.

[0028] In some embodiments, the cell culture medium has an osmolarity of 300-400 mOsm / kg.

[0029] In some embodiments, the marine embryonic pluripotent stem cell is in a suspension.

[0030] In some embodiments, the marine embryonic pluripotent stem cell is not adhered to a solid support in the suspension.

[0031] In some embodiments, each aggregate of the aggregates comprises between 50 to 1,000 fish adipocyte cells.

[0032] In some embodiments, each aggregate of the aggregates comprises between 2 to 1,000 fish myocyte cells.

[0033] In some embodiments, the cells in the suspension are not adhered to a solid support.

[0034] In some embodiments, the composition further comprises an edible carrier.

[0035] In some embodiments, the composition is an edible composition.

[0036] In some embodiments, the composition is a food product or an ingredient thereof.

[0037] Unless otherwise defined, all technical and / or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and / or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.

[0038] Further embodiments and the full scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figs. 1A-1E include micrographs and fluorescent micrographs showing two-dimensional (2D) cultures of fish embryonic stem cell (ESC) lines. (1A-1C) Representative phase images of 3 ESC lines. (1D-1E) Immunofluorescence staining of pluripotency key markers Oct4 (green) and Nanog (green) in fish ESCs (passage 60). Nuclei were counter stained using DAPI (blue).

[0040] Fig. 2 includes a vertical bar graph showing the calculated population doubling time (PDT) and quantitative PCR (qPCR) analysis of the key pluripotency genes: Oct4, Nanog, and SOX2, following long term 2D culture (passage > 20).

[0041] Figs. 3A-3B include phase images of three-dimensional (3D) cultures of fish ESC. (3A) Aggregates of the dESC54.2 cell line cultured in XF+++ media. (3B) Single cells of the dESCs54.2 cell line cultured in CM100 + 100 ng / ml epidermal growth factor (EGF).

[0042] Figs.4A-4B include phase image and a fluorescent micrograph showing induced adipogenesis in 2D adherent cultures of fish ESC. Lipid droplets accumulation was demonstrated by (4A) phase contrast microscopy image and (4B) positive immunofluorescence Bodipy staining (green) following 6 days of differentiation.

[0043] Figs. 5A-5C include phase image, a fluorescent micrograph, and a graph showing induced adipogenesis in 3D suspension cultures of fish ESC. Lipid droplets accumulation was demonstrated by (5A) phase contrast microscopy image and (5B) positive immunofluorescence Bodipy staining (green) following 14 days of differentiation. (5C) Expression analysis of adipogenic genes compared to control (undifferentiated cells in 2D) performed by quantitative RT-PCR.

[0044] Figs. 6A-6D include phase image, fluorescent microscopy, and a vertical bar graph showing induced myogenesis in 2D adherent cultures of fish ESC. (6A) Phase contrast microscopy image of fish myocytes (elongated morphology resembling muscle fibers). (6B-6C) Representative immunofluorescence staining for myogenic proteins: SMA (B, green) and Myh (C, green). Nuclei were counter stained by DAPI (blue). (6D) qPCR analysis of myogenic genes: SMA, MYH, DESMIN and CNN, following myogenic differentiation.

[0045] Figs. 7A-7C include phase image, a fluorescent micrograph, and a vertical bar graph showing induced myogenesis in 3D suspension cultures of fish ESC. (7A) Phasecontrast microscopy image of fish myocytes. (7B) Representative immunofluorescence staining for myogenic proteins SMA (green). Nuclei were counter stained by DAPI (blue). (7C) qPCR analysis of myogenic genes: SMA, MYH and DESMIN following myogenic differentiation.DETAILED DESCRIPTION OF THE INVENTIONMethods

[0046] According to the first aspect, there is provided a method for maintaining pluripotency of a marine embryonic stem cell in a culture.

[0047] According to another aspect, there is provided a method for differentiating a marine embryonic pluripotent stem cell in a culture into an adipocyte cell.

[0048] According to another aspect, there is provided a method for differentiating a marine embryonic pluripotent stem cell in a culture into a myocyte cell.

[0049] In some embodiments, a culture is an in vitro or ex vivo culture. In some embodiments, the method of the invention is an in vitro or ex vivo method. In some embodiments, the method of the invention is not performed in the body of a marine organism.

[0050] According to another aspect, there is provided a method for increasing amount or content of at least one fatty acid in a marine cell. In some embodiments, the marine cell is derived or differentiated from a pluripotent embryonic stem cell according to the method of the invention. In some embodiments, the at least one fatty acid comprises an unsaturated fatty acid. In some embodiments, an unsaturated fatty acid comprises polyunsaturated fatty acid. In some embodiments, the fatty acid comprises omega 3 fatty acid. In some embodiments, the unsaturated fatty acid comprises omega 3 fatty acid. In some embodiments, the polyunsaturated fatty acid comprises omega 3 fatty acid. In some embodiments, increasing is compared to control. In some embodiments, a cell is a target cell, as disclosed herein.

[0051] In some embodiments, “increase”, “increasing” or “increased” refer to an increase of at least 5%, 10%, 20%, 50%, 75%, 100%, 200%, 350%, 500%, 650%, 750%, 800%, 900%, 950%, 1,000%, or any value and range therebetween. Each possibility represents a separate embodiment of the invention.

[0052] In some embodiments, “increase”, “increasing” or “increased” refer to an increase of 5-100%, 10-200%, 20-200%, 50-300%, 75-250%, 5-300%, 20-250%, 5-1,000%, 10-1,000%, 20-1,000%, 50-1,000%, 75-1,000%, 100-1,000%, 200-1,000%, 350-1,000%, 500-1,000%, 650-1,000%, 750-1,000%, 800-1,000%, 900-1,000%, or 950-1,000%. Each possibility represents a separate embodiment of the invention.

[0053] In some embodiments, the method comprises isolating an embryonic stem cell from an embryo of a marine organism.

[0054] Methods for isolating an embryonic stem cell are common and would be apparent to one of ordinary skill in the art. Non-limiting examples for such methods include, but are not limited to: Blastocyst isolation and inner cell mass extraction; Immunosurgery technique; Mechanical dissection of inner cell mass; Laser-assisted isolation of inner cell mass; Fluorescence-activated cell sorting (FACS) with stem cell-specific markers; Magnetic-activated cell sorting (MACS) using stem cell surface antigens; Density gradient centrifugation; Differential plating techniques; Feeder layer-based selection; Serum-free culture conditions for selective growth; Colony picking and subculturing; Microfluidic device-based isolation; Antibody-based affinity purification; Size-based separation using microsieves; Dielectrophoresis for cell separation; Complement-mediated selection; Genetic selection using reporter genes; Single-cell isolation using micromanipulators; Enzymatic digestion of blastocysts followed by selective culture; and Parthenogenetic activation of oocytes for stem cell derivation, to name a few.

[0055] In some embodiments, isolating is from the inter cell mass (ICM). In some embodiments, isolating is from the epiblast. In some embodiments, isolating is from the ICM and the epiblast.

[0056] In some embodiments, the method comprises culturing isolated embryonic stem cell from step in a cell culture medium comprising: (i) a basal medium; and (ii) serum or a serum replacement.

[0057] In some embodiments, the method comprises: (a) isolating an embryonic stem cell from an embryo of a marine organism; and culturing isolated embryonic stem cell from step (a) in a cell culture medium comprising: (i) a basal medium; and (ii) serum or a serum replacement.

[0058] In some embodiments, the method comprises contacting marine embryonic pluripotent stem cell with an effective amount of a differentiation agent comprising retinoic acid, a derivative thereof, or any combination thereof.

[0059] As used herein, the term "retinoic acid" may refer to a metabolite of vitamin A that plays crucial roles in various biological processes, including cell differentiation, proliferation, and embryonic development. Retinoic acid is a lipophilic molecule with a chemical structure consisting of a cyclohexene ring attached to a polyene side chain terminating in a carboxylic acid group.

[0060] As used herein, the term "retinoic acid derivative" may refer to a compound that is structurally related to retinoic acid or shares similar biological activities. These derivatives may be naturally occurring or synthetically produced molecules that retain some or all of the functional characteristics of retinoic acid. Retinoic acid derivatives may include, but are not limited to, retinol, retinal, retinyl esters, synthetic retinoids, and various isomers of retinoic acid such as all-trans retinoic acid, 9-cis retinoic acid, and 13-cis retinoic acid. These compounds may differ from retinoic acid in their chemical structure, such as modifications to the cyclohexene ring, alterations in the polyene side chain, or the addition of functional groups. Retinoic acid derivatives may exhibit similar biological effects to retinoic acid, including roles in cell differentiation, proliferation, and embryonic development, and may be used in various therapeutic, cosmetic, or research applications.

[0061] In some embodiments, a retinoic acid derivative is selected from: Retinoic acid derivatives may include: All-trans retinoic acid (ATRA), 9-cis retinoic acid, 13-cis retinoic acid (isotretinoin), Retinol (vitamin A), Retinal (retinaldehyde), Retinyl palmitate, Retinyl acetate, Etretinate, Acitretin, Adapalene, Tazarotene, Bexarotene, Alitretinoin, Tretinoin, Motretinide, Fenretinide, Tamibarotene, Arotinoid, Am80 (tamibarotene), CD437 (6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid), LG100268, LGD1069 (targretin), 4-oxo-retinoic acid, 4-hydroxy-retinoic acid, Retinyl propionate, Retinyl linoleate, Retinyl stearate, Retinyl oleate, Retinyl myristate, Retinyl laurate, or any combination thereof.

[0062] In some embodiments, the cell culture medium further comprises: basic fibroblast growth factor (bFGF), IL-6 / IL-6Ra chimera, epidermal growth factor (EGF), a non-essential amino acid or a plurality thereof, an antibiotic agent, or any combinationthereof. In some embodiments, the cell culture medium further comprises basic fibroblast growth factor (bFGF). In some embodiments, the cell culture medium further comprises IL-6 / IL-6Ra chimera. In some embodiments, the cell culture medium further comprises epidermal growth factor (EGF). In some embodiments, the cell culture medium further comprises a non-essential amino acid or a plurality thereof. In some embodiments, the cell culture medium further comprises an antibiotic agent.

[0063] In some embodiments, a basal medium comprises: L-15, DMEM, F12, or a combination thereof. In some embodiments, a basal medium comprises L-15. In some embodiments, a basal medium comprises DMEM. In some embodiments, a basal medium comprises F12. In some embodiments, a basal medium comprises a combination of L-15 and DMEM. In some embodiments, a basal medium comprises a combination of L-15 and F12. In some embodiments, a basal medium comprises a combination of DMEM and F12. In some embodiments, a basal medium comprises a combination of L-15, DMEM, and F12.

[0064] As used herein, the term “basal medium” may refer to a basic cell culture medium that provides essential nutrients, salts, and other components necessary to support cell survival and growth. This medium typically contains a balanced mixture of inorganic salts, amino acids, vitamins, glucose, and other nutrients, but may lack additional growth factors or supplements. Basal medium serves as a foundation for cell culture and may be customized or supplemented with additional components to meet the specific requirements of different cell types or experimental conditions. It may be used in various applications, including cell maintenance, expansion, and differentiation studies in fields such as cell biology, tissue engineering, and biotechnology.

[0065] In some embodiments, the medium is devoid of yeast or plant hydrolysate. In some embodiments, a plant is a soy plant. In some embodiments, a plant hydrolysate is soy lysates. In some embodiments, the medium is devoid of yeast lysate. In some embodiments, the medium is devoid of yeast, plant peptones, a hydrolysate, or any combination thereof.

[0066] In some embodiments, culturing comprises 2D culturing. In some embodiments, culturing comprises 3D culturing. In some embodiments, culturing comprises a combination of 2D culturing and 3D culturing.

[0067] As used herein, the term “two-dimensional (2D) culturing” may refer to a method of growing cells in a single layer on a flat surface, such as a petri dish, flask, or other culture vessel. This technique typically involves culturing cells on a two-dimensional substrate, where the cells adhere to and spread across the surface, forming a monolayer. Two-dimensional culturing may allow for easy observation and manipulation of cells and is commonly used in various biological and biomedical research applications, including cell biology studies, drug screening, and toxicity testing. This method may contrast with three-dimensional culturing techniques, which aim to more closely mimic in vivo cellular environment.

[0068] As used herein, the term “three-dimensional (3D) culturing” may refer to a method of growing cells in a three-dimensional environment that more closely mimics the natural in vivo conditions. This technique typically involves culturing cells within a matrix or scaffold that provides support and allows for cell growth and interaction in all spatial dimensions. Three-dimensional culturing may enable cells to form complex structures, maintain more physiologically relevant cell-cell and cell-matrix interactions, and exhibit behaviors that are more representative of in vivo counterparts. This method may be used in various applications, including tissue engineering, drug discovery, cancer research, and stem cell studies, potentially providing more accurate models of cellular behavior and tissue function compared to traditional two-dimensional culturing techniques.

[0069] In some embodiments, 2D culturing comprises culturing on support. In some embodiments, a support comprises a surface. In some embodiments, support comprises a plate or a surface thereof. In some embodiments, support comprises a solid support. In some embodiments, support comprises semi-solid support. In some embodiments, semisolid support comprises a gel, a scaffold, or the like. In some embodiments, a gel comprises any matrix comprising water and a polymer, wherein the water is dispersed within a three-dimensional mesh made of linked or cross-linked polymer.

[0070] In some embodiments, 3D culturing comprises or is a suspension or a cell suspension. In some embodiments, 3D culturing is devoid of a solid or a semi support. In some embodiments, in 3D culturing, cells are suspended support-less in a liquid medium. In some embodiments, culturing in 3D is solid support-free culturing.

[0071] As used herein, the term “cell suspension” may refer to a mixture in which cells are dispersed and suspended in a liquid medium. This suspension may contain individual cells or aggregates of cells that are distributed throughout the liquid, typically in a relatively uniform manner. Cell suspensions may be prepared from various sources, including cultured cells, tissue samples, or blood, and may be used in a wide range of biological and medical applications. These applications may include, but are not limited to, cell culture initiation, flow cytometry analysis, cell counting, drug screening, or transplantation studies. The liquid medium in a cell suspension may be a buffer solution, growth medium, or other appropriate fluid that maintains cell viability and supports the intended experimental or clinical use.

[0072] In some embodiments, culturing comprises culturing in 2D followed by culturing in 3D.

[0073] In some embodiments, culturing in 2D is for a period of between 1 and 100 days, 1 and 200 days, 1 and 300 days, 1 and 30 days, 1 and 40 days, 2 and 50 days, 2 and 350 days, 2 and 60 days, 2 and 80 days, 3 and 150 days, 50 and 200 days, 60 and 180 days, 70 and 190 days, 70 and 150 days, or 3 and 400 days. Each possibility represents a separate embodiment of the invention. In some embodiments, a 2D culture is a continuous culture. In some embodiments, continuous is for at least 1 day. In some embodiments, continuous is for 1 day or more.

[0074] In some embodiments, culturing in 2D is for a number of passages ranging between 30 and 100, 35 and 100, 40 and 100, 50 and 100, 45 and 120, 60 and 110, 70 and 100, 80 and 100, 90 and 100, and 90 and 120. Each possibility represents a separate embodiment of the invention. In some embodiments, a passage correlates to 1-2, or 1-3 days of culturing. In some embodiments, a passage is performed every 1-2 days, or 1-3 days. In some embodiments, a passage correlates to 16 to 48 hr. Each possibility represents a separate embodiment of the invention.

[0075] In some embodiments, culturing in 3D is for a period of between 1 and 50 days, 1 and 40 days, 1 and 35 days, 1 and 20 days, 1 and 60 days, 1 and 75 days, 2 and 50 days, 2 and 40 days, 3 and 65 days, 3 and 80 days, 2 and 55 days, 10 and 30 days, or 10 and 25 days. Each possibility represents a separate embodiment of the invention.

[0076] In some embodiments, cells cultured in 3D are in the form of cell aggregates, single solitary cells, or a combination thereof.

[0077] As used herein, the term “cell aggregates” may refer to clusters or groups of cells that adhere to each other and form three-dimensional structures. These aggregates may occur naturally or be artificially induced in cell culture conditions. Cell aggregates may vary in size, shape, and composition, potentially containing a single cell type or multiple cell types. They may exhibit different properties compared to individual cells, including altered gene expression, cell-cell interactions, and responses to external stimuli. Cell aggregates may be used in various research applications, such as studying tissue formation, cell differentiation, drug screening, and modeling of complex biological systems. In some contexts, cell aggregates may also be referred to as spheroids, organoids, or microtissues, depending on their specific characteristics and formation methods.

[0078] As used herein, the term “solitary cells” may refer to individual cells that exist independently and are not physically attached to or in direct contact with other cells. These cells may be found in suspension or adhered to a substrate but maintain their individual identity without forming multicellular structures or aggregates. Solitary cells may be observed in various contexts, including certain stages of cell culture, specific cell types in vivo, or as a result of experimental manipulations. The study of solitary cells may provide insights into individual cell behavior, properties, and responses to stimuli, distinct from the collective behaviors observed in cell populations or aggregates.

[0079] Methods for determining form of cells, such as solitary cells, cell aggregates, or a combination thereof, are common and would be apparent to one of ordinary skill in the art. Non-limiting examples for such methods include, but are not limited to, Methods for determining cell aggregates may include: Microscopy techniques, such as: Light microscopy, Phase contrast microscopy, Fluorescence microscopy, Confocal microscopy, Electron microscopy; Flow cytometry analysis; Image analysis software, such as: Automated cell counting and sizing algorithms and / or Machine learning-based image recognition; Sedimentation assays; Hanging drop method; Microfluidic devices for aggregate detection and characterization; Coulter counter or other particle sizing instruments; Laser diffraction particle size analysis; Dynamic light scattering; Optical coherence tomography; Atomic force microscopy; Impedance-based cell analysis systems; 3D cell culture imaging systems; Time-lapse video microscopy; Fluorescent labeling and tracking of individual cells within aggregates; Histological sectioning and staining; Biochemical assays for cell-cell adhesion molecules; Single-cell sequencing toidentify cellular composition of aggregates; Magnetic levitation for aggregate formation and analysis; or Microwell array systems for controlled aggregate formation and characterization, to name a few.

[0080] In some embodiments, the method further comprises a step comprising differentiating cultured isolated embryonic cell in a pluripotent state, into a target cell type. In some embodiments, the differentiating step is after step (b) of the method of the invention.

[0081] In some embodiments, the target cell type comprises an adipocyte, an adipocytelike cell, and / or a precursor cell thereof. In some embodiments, the target cell comprises a myocyte, a myocyte-like cell, and / or a precursor thereof. In some embodiments, the target cell comprises a mixture of target cells, comprising any mixture of an adipocyte, an adipocyte-like cell, and / or a precursor cell thereof, a myocyte, a myocyte-like cell, and / or a precursor thereof. In some embodiments, the target cell comprises a fat or lipid accumulating cell. In some embodiments, the target cell comprises fat or lipid droplets. In some embodiments, a fat or lipid accumulating cell comprises an adipocyte or an adipocyte-like cell. In some embodiments, a target cell comprising fat or lipid droplets is an adipocyte or an adipocyte-like cell.

[0082] As used herein, the term “adipocyte” may refer to a specialized cell type primarily responsible for storing energy as fat. These cells, also known as fat cells or lipocytes, are the main components of adipose tissue. Adipocytes may contain a large lipid droplet that occupies most of the cell volume, pushing the nucleus and other organelles to the periphery. They play a crucial role in energy metabolism, storing excess energy in the form of triglycerides and releasing it as free fatty acids when needed. Adipocytes may also function as endocrine cells, secreting various hormones and cytokines that influence metabolism, appetite, and other physiological processes. There are two main types of adipocytes: white adipocytes, which store energy, and brown adipocytes, which are involved in thermogenesis.

[0083] Methods for determining whether a cell is an adipocyte or an adipocyte-like cell are common and would be apparent to one of ordinary skill in the art. Non-limiting examples of such methods include, but are not limited to: Microscopy techniques, including: Light microscopy, Phase contrast microscopy, Fluorescence microscopy, Confocal microscopy, and Electron microscopy; Histological staining, including:Bodipy staining for lipid droplets, Hematoxylin and eosin (H& E) staining, and Nile Red staining for neutral lipids; Immunohistochemistry or immunofluorescence for adipocytespecific markers; Flow cytometry analysis; Gene expression analysis, including: RT-PCR for adipocyte-specific genes, and RNA sequencing; Protein analysis, including: Western blotting for adipocyte-specific proteins, and ELISA for adipokines; Lipidomics analysis; Metabolic assays, including: Glucose uptake assays, Lipolysis assays, Insulin sensitivity assays; Adipokine secretion measurements; Cell size and morphology analysis using automated imaging systems; Magnetic resonance imaging (MRI) for in vivo adipocyte detection; Computed tomography (CT) scanning for adipose tissue visualization; Dual-energy X-ray absorptiometry (DEXA) for body composition analysis; Bioelectrical impedance analysis (BIA) for estimating body fat percentage; Adipocyte differentiation assays from precursor cells; Single-cell RNA sequencing for adipocyte subpopulation identification; Laser capture microdissection for isolating individual adipocytes; Atomic force microscopy for studying adipocyte membrane properties; Raman spectroscopy for non-invasive lipid content analysis; and Adipocytespecific reporter gene assays in transgenic models, to name a few.

[0084] As used herein, the term “myocyte” may refer to a muscle cell, also known as a muscle fiber. Myocytes are specialized cells forming the basic unit of muscle tissue. These cells are characterized by their elongated shape and their ability to contract in response to stimuli. Myocytes contain numerous myofibrils, which are composed of contractile proteins such as actin and myosin. There are several types of myocytes, including skeletal muscle cells, cardiac muscle cells, and smooth muscle cells, each with distinct characteristics and functions. Myocytes play crucial roles in various physiological processes, including movement, posture maintenance, heart function, and regulation of blood flow in vessels.

[0085] Methods for determining whether a cell is a myocyte or a myocyte-like cell are common and would be apparent to one of ordinary skill in the art. Non-limiting examples of such methods are described herein, with the following exceptions: Histological staining, including: Masson's trichrome staining, and Periodic acid-Schiff (PAS) staining; Immunohistochemistry or immunofluorescence for myocyte-specific markers; Gene expression analysis including RT-PCR for myocyte-specific genes; Protein analysis, including: Western blotting for myocyte-specific proteins, and ELISA for myocyte-related factors; Electrophysiological measurements, including: Patch-clamptechniques, and Microelectrode recordings; Contractility assays; Calcium imaging; Myocyte-specific reporter gene assays; Single-cell RNA sequencing for myocyte subpopulation identification; Laser capture microdissection for isolating individual myocytes; Atomic force microscopy for studying myocyte membrane properties; Raman spectroscopy for non-invasive analysis of myocyte composition; Myocyte differentiation assays from precursor cells; Metabolic assays, including: Glucose uptake assays, and Fatty acid oxidation assays; Mitochondrial function assays; Sarcomere length measurements; Myofiber typing using ATPase staining; and In vivo imaging techniques, including: Magnetic resonance imaging (MRI) for muscle tissue visualization, and Positron emission tomography (PET) for metabolic activity assessment, to name a few.

[0086] In some embodiments, differentiating comprises contacting a cultured isolated embryonic cell in a pluripotent state with an effective amount of a fatty acid. In some embodiments, a fatty acid comprises an unsaturated fatty acid, a saturated fatty acid, or a combination thereof. In some embodiments, a fatty acid comprises a fatty acid unique and / or highly abundant in a fish or a cell thereof. In some embodiments, “highly” is compared to a control organism (or a cell thereof) that is not a fish. In some embodiments, a control organism comprises a mammal, an avian, a reptile, an amphibian, a plant, or any combination thereof. In some embodiments, unsaturated comprises monounsaturated, polyunsaturated, or any combination thereof.

[0087] In some embodiments, differentiating comprises contacting a cultured isolated embryonic cell in a pluripotent state with an effective amount of a differentiation agent comprising: insulin, oleic acid, retinoic acid, or any combination thereof.

[0088] In some embodiments a target cell is an adipocyte, and a differentiation agent is an adipogenesis inducing agent. In some embodiments, an adipogenesis inducing agent comprises insulin, oleic acid, or insulin and oleic acid.

[0089] In some embodiments, a target adipocyte comprises an unsaturated fatty acid in an increased amount compared to a control cell. In some embodiments, an unsaturated fatty acid comprises a polyunsaturated fatty acid (PUFA). In some embodiments, an unsaturated fatty acid comprises omega 3 fatty acid. In some embodiments, a polyunsaturated fatty acid (PUFA) comprises omega 3 fatty acid. In some embodiments,a target adipocyte comprises omega 3 fatty acid in an increased amount compared to a control cell.

[0090] Methods for quantifying or determining the amount of polyunsaturated fatty acid(s) (PUFA) are common and would be apparent to one of ordinary skill in the art. Non-limiting examples for such methods include, but are not limited to: Gas chromatography (GC) analysis; High-performance liquid chromatography (HPLC); Mass spectrometry (MS) techniques, including: GC-MS, LC-MS, and Tandem mass spectrometry (MS / MS); Nuclear magnetic resonance (NMR) spectroscopy; Fourier-transform infrared spectroscopy (FTIR); Thin-layer chromatography (TLC); Colorimetric assays; Enzymatic assays; Near-infrared spectroscopy (NIR); Raman spectroscopy; Capillary electrophoresis; Flame ionization detection (FID) coupled with GC; Ultraviolet-visible spectrophotometry; Fluorescence spectroscopy; Chemiluminescence detection methods; Isotope ratio mass spectrometry (IRMS); Matrix-assisted laser desorption / ionization (MALDI) mass spectrometry; Supercritical fluid chromatography (SFC); Derivatization techniques followed by chromatographic analysis; and Lipidomics approaches using high-resolution mass spectrometry, to name a few.

[0091] In some embodiments, a control comprises a control cell. In some embodiments, a control cell is a lipid non-accumulating cell. In some embodiments, a control cell is not an adipocyte and / or an adipocyte-like cell. In some embodiments, a control cell comprises a cell cultured not according to the method of the invention. In some embodiments, a control cell is devoid of fat and / or lipid droplets. In some embodiments, a control cell is devoid of lipid droplets determined as disclosed herein.

[0092] In some embodiments, differentiating further comprises subjecting the contacted cultured isolated embryonic cell to a temperature ranging between 18 °C and 28 °C, 19 °C and 28 °C, 20 °C and 28 °C, 21 °C and 28 °C, 22 °C and 28 °C, 23 °C and 28 °C, 24 °C and 28 °C, or 25 °C and 28 °C. In some embodiments, differentiating further comprises subjecting the contacted cultured isolated embryonic cell to a temperature ranging between 34 °C and 40 °C, 35 °C and 40 °C, 36 °C and 40 °C, 37 °C and 40 °C, 38 °C and 40 °C, or 39 °C and 40 °C. Each possibility represents a separate embodiment of the invention. In some embodiments, differentiating comprises differentiating into an adipocyte. In some embodiments, differentiating comprises differentiating into amyocyte. In some embodiments, differentiating comprises differentiating into a plurality or mixture of cells, comprising an adipocyte and a myocyte.

[0093] In some embodiments, a target cell comprises a monocyte, and a differentiation agent is a myogenesis inducing agent. In some embodiments, a myogenesis inducing agent comprises retinoic acid.

[0094] In some embodiments, a marine organism comprises a fish. In some embodiments, a cell as disclosed herein is obtained, derived, or both, from any one of: a fish or a tissue thereof, an embryo thereof, or any combination thereof.

[0095] In some embodiments, a serum comprises a serum of a livestock. In some embodiments, a serum comprises a fetal serum, fish serum, or both. In some embodiments, a serum comprises a bovine serum. In some embodiments, a serum comprises a fetal bovine serum.

[0096] In some embodiments, the cell culture medium has or is characterized by an osmolarity of 300-400 mOsm / kg, 310-400 mOsm / kg, 320-400 mOsm / kg, 330-400 mOsm / kg, 340-400 mOsm / kg, 350-400 mOsm / kg, 360-400 mOsm / kg, 370-400 mOsm / kg, 380-400 mOsm / kg, or 390-400 mOsm / kg. Each possibility represents a separate embodiment of the invention.

[0097] In some embodiments, a marine embryonic pluripotent stem cell is in a suspension. In some embodiments, a marine embryonic pluripotent stem cell is dispersed or suspended in liquid, such as, but not limited to cell culture or growth medium. In some embodiments, a marine embryonic pluripotent stem cell is not adhered to a support in the suspension. In some embodiments, a marine embryonic pluripotent stem cell is not adhered to a solid or semi-solid support in suspension.Compositions

[0098] According to another aspect, there is provided a composition comprising a suspension of fish embryonic stem cells, wherein the fish stem cells are not in the form of embryoid body. In some embodiments, the composition is devoid of embryoid body / bodies.

[0099] According to another aspect, there is provided a composition comprising a suspension of fish adipocyte cells, wherein the fish adipocyte cells are present in the suspension in the form of aggregates, solitary cells, or a combination thereof.

[0100] According to another aspect, there is provided a composition comprising a suspension of fish myocyte cells, wherein the fish myocyte cells are present in the suspension in the form of: solitary cells, aggregates, or a combination thereof.

[0101] In some embodiments, each aggregate of the aggregates comprises between 2 to 1,000, 50 to 1,000, 100 to 1,000, 200 to 1,000, 250 to 1,000, 350 to 1,000, 500 to 1,000, 750 to 1,000, 800 to 1,000, 900 to 1,000, or 950 to 1,000 fish adipocyte cells. Each possibility represents a separate embodiment of the invention. In some embodiments, each aggregate of the aggregates comprises between 2 to 1,000, 20 to 1,000, 100 to 1,000, 200 to 1,000, 250 to 1,000, 350 to 1,000, 500 to 1,000, 750 to 1,000, 800 to 1,000, 900 to 1,000, or 950 to 1,000 fish adipocyte cells on average. Each possibility represents a separate embodiment of the invention. In some embodiments, between 2 to 1,000, 20 to 1,000, 100 to 1,000, 200 to 1,000, 250 to 1,000, 350 to 1,000, 500 to 1,000, 750 to 1,000, 800 to 1,000, 900 to 1,000, or 950 to 1,000 fish adipocyte cells make up an aggregate. Each possibility represents a separate embodiment of the invention. In some embodiments, a cell aggregate refers to any cell aggregate comprising 2 cells or more. In some embodiments, a cell aggregate refers to any cell aggregate comprising at least 2 cells. In some embodiments, a cell aggregate refers to any cell aggregate comprising a plurality of cells.

[0102] As used herein, the term “plurality” refers to any integer being equal to or greater than 2.

[0103] In some embodiments, the composition further comprises an edible carrier. In some embodiments, the composition further comprises a nutraceutically acceptable carrier. In some embodiments, an edible carrier comprises or is a nutraceutically acceptable carrier. In some embodiments, a nutraceutically acceptable carrier comprises or is an edible carrier.

[0104] As used herein, the term “edible carrier” may refer to a substance or material that is safe for human or animal consumption and serves as a vehicle or medium for delivering other ingredients, compounds, or active agents. Edible carriers may be used in various food, pharmaceutical, or nutraceutical applications to facilitate the administration, distribution, or absorption of desired components. These carriers may be derived from natural sources, synthetically produced, or a combination of both. Edible carriers may take various forms, including but not limited to liquids, gels, powders,emulsions, or solid matrices. They may be selected based on their compatibility with the active ingredients, stability, taste, texture, and ability to enhance bioavailability or mask undesirable flavors.

[0105] As used herein, the term “nutraceutically acceptable carrier” may refer to a substance or material that is safe for human or animal consumption and is suitable for use in nutraceutical formulations. These carriers may serve as vehicles or media for delivering bioactive compounds, nutrients, or other health-promoting ingredients. Nutraceutically acceptable carriers may be derived from natural sources, synthetically produced, or a combination of both, and are typically chosen for their compatibility with active ingredients, stability, and ability to enhance the overall efficacy or delivery of the nutraceutical product. They may take various forms such as liquids, powders, gels, or solid matrices, and are often selected to improve bioavailability, mask undesirable tastes, or provide specific release profiles of the active components. These carriers may also contribute to the preservation, texture, or other physical properties of the nutraceutical formulation.

[0106] In some embodiments, the composition is an edible composition. In some embodiments, the composition is a food product or a foodstuff. In some embodiments, the composition is an ingredient of a food product or a foodstuff. In some embodiments, the composition is further mixed or combined with at least one additional ingredient so as to prepare, make, manufacture, or any combination thereof, a food product or a foodstuff.

[0107] According to some embodiments, there is provided a method for preparing a food product or a foodstuff, comprising mixing the composition of the invention with at least one additional food ingredient.General

[0108] Any concentration ranges, percentage range, or ratio range recited herein are to be understood to include concentrations, percentages or ratios of any integer within that range and fractions thereof, such as one tenth and one hundredth of an integer, unless otherwise indicated.

[0109] Any number range recited herein relating to any physical feature, such as polymer subunits, size or thickness, are to be understood to include any integer within the recited range, unless otherwise indicated.

[0110] In the discussion unless otherwise stated, adjectives such as “substantially” and “about” modifying a condition or relationship characteristic of a feature or features of an embodiment of the invention, are understood to mean that the condition or characteristic is defined to within tolerances that are acceptable for operation of the embodiment for an application for which it is intended. Unless otherwise indicated, the word “or” in the specification and claims is considered to be the inclusive “or” rather than the exclusive or, and indicates at least one of, or any combination of items it conjoins.

[0111] It should be understood that the terms “a” and “an” as used above and elsewhere herein refer to “one or more” of the enumerated components. It will be clear to one of ordinary skill in the art that the use of the singular includes the plural unless specifically stated otherwise. Therefore, the terms “a”, “an” and “at least one” are used interchangeably in this application.

[0112] For purposes of better understanding the present teachings and in no way limiting the scope of the teachings, unless otherwise indicated, all numbers expressing quantities, percentages or proportions, and other numerical values used in the specification and claims, are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.

[0113] As used herein, the term “about” refers to ±10%.

[0114] In the description and claims of the present application, each of the verbs, “comprise”, “include”, and “have” and conjugates thereof, are used to indicate that the object or objects of the verb are not necessarily a complete listing of components, elements or parts of the subject or subjects of the verb.

[0115] Other terms as used herein are meant to be defined by their well-known meanings in the art.

[0116] Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the variousembodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.

[0117] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments unless the embodiment is inoperative without those elements.EXAMPLES

[0118] Generally, the nomenclature used herein, and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, " Molecular Cloning: A laboratory Manual" Sambrook et al., (1989); " Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., " Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, " A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., " Recombinant DNA", Scientific American Books, New York; Birren et al. (eds.) " Genome Analysis: A Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U. S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; " Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J. E., ed. (1994); " Culture of Animal Cells - A Manual of Basic Technique" by Freshney, Wiley-Liss, N. Y. (1994), Third Edition; " Current Protocols in Immunology" Volumes I-III Coligan J. E., ed. (1994); Stites et al. (eds), " Basic and Clinical Immunology" (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), " Strategies for Protein Purification and Characterization - A Laboratory Course Manual" CSHL Press (1996); all of which are incorporated by reference. Other general references are provided throughout this document.Materials and MethodsTwo-dimensional (2D) Maintenance and Subculturing

[0119] Fish embryonic stem cells (fESCs) were cultured in 2D on matrigel / gelatin-coated vessels using CM100+++ / 5CM50+++ or XF+++ media at 22 °C. fESCs were sub-cultured when 70-90% confluency was reached. ROCK inhibitor was added at a 1:1,000 dilution for one hour at either 22 °C or 37 °C. The spent medium was aspirated, and the cells were washed once with phosphate-buffered saline (PBS, without calcium and magnesium) to remove serum residuals. Trypsin-EDTA (0.25%) was added to cover the monolayer, and the vessel was incubated at room temperature for 5 minutes to detach the cells. To neutralize the trypsin DMEM+10% FBS was added then the cells were gently scraped using cell scraper. Detachment was confirmed under a microscope. The detached cells were collected into a sterile tube and centrifuged under 1,300 rpm for 5 min. The supernatant was aspirated, and the cells were resuspended using fresh media. The cell suspension was pipetted gently to ensure a single-cell suspension and transferred to a new sterile culture vessel at the desired seeding density (1:3 or 1:4) on matrigel / gelatin-coated vessels. The vessels were placed in a 22 °C incubator. All procedures were performed under sterile conditions.Table 1. CM100+++ mediumTable 2. 5% SR- CM50+++ mediumThree-dimensional (3D) Maintenance

[0120] Fish embryonic stem cells (fESCs) were cultured in 2D on matrigel / gelatin-coated vessels using CM100+++ / 5CM50+++ or XF+++ media at 22 °C.

[0121] Cells were adapted from adherent to suspension culture using a stepwise protocol. Adherent cells at 70-90% confluency were detached using 0.25% trypsin-EDTA and resuspended in growth medium as mentioned in 2D maintenance and subculturing protocol. ROCK inhibitor was added both before and after cell splitting. The cell suspension was transferred to untreated, low-attachment plates or flasks to allow suspension cell growth. Cells were maintained at 22 °C or at 37 °C with 5% CO2, and the medium was replaced every 2-3 days by centrifugation, 1,300 rpm for 5 min. During adaptation, cells were monitored microscopically for single-cell or clump morphology and viability. Subculturing was performed by gently pipetting the suspension and diluting the cells into fresh medium at the desired seeding density. Complete adaptationwas achieved when cells exhibited consistent growth and viability in suspension. All procedures were conducted under sterile conditions.Table 3. XF+++ mediumTable 4. 20×F50+++ medium*MEMTable 5.20xF’50+++ mediumAdipogenesis

[0122] Fish embryonic stem cells (fESCs) were cultured in 2D on matrigel / gelatin-coated plates using CM100+++ / 5CM50+++ or XF+++ media at 22 °C. The cells were transferred using 0.25% trypsin-EDTA into suspension cultures on untreated plates with CM100+++ / 5CM50+++ or XF+++ medium and incubated at 37 °C for 3 days (Adaptation from 2D to 3D step). The next day, the media was changed to 5%YF0 supplemented with 10 pg / mL insulin and incubated at 37 °C for 3 days (Adipogenic induction step). On the next day, the media was changed to 5%YF0 supplemented with 10 pg / mL insulin and 50 pM oleic acid and incubated at 37 °C for 3 days (Adipogenesis step).Table 6. Timeline protocol for inducing adipogeneisTable 7. 5% YF0 media +++ medium0123] The 5% YFO media +++ medium was further supplemented with insulin (Insulin solution, Human recombinant, cat: I9278, Sigma) and Oleic acid (Cat: 01008-5G, Sigma).Myogenesis

[0124] Fish embryonic stem cells (fESCs) were cultured in 2D on matrigel / gelatin-coated plates using CM100+++ / 5CM50+++ or XF+++ media at 22 °C. The cells were transferred using 0.25% trypsin-EDTA into suspension cultures on untreated plates with CM100+++ / 5CM50+++ or XF+++ medium and incubated at 22 °C or 37 °C for another day (Adaptation from 2D to 3D step). The next day the media was changed to CM100+++ Diff or 5CM50+++ Diff or XF+++ supplemented with 37 pM Retinoic acid (RA) and incubated at 22 °C / 37 °C for 6 days (Myogenesis induction step).Table 8. Timeline protocol for inducing myogeneisTable 9. CM1000+++Diff mediumTable 10. 5% SR- CM50+++Diff mediumwas further supplemented with retinoic acid (Cat. R2625, Sigma).EXAMPLE 1

[0126] The inventors show the growth of fish embryonic stem cells (ESCs) in suspension and their differentiation into adipocytes and myocytes. In 2D culture conditions, three fish ESC lines were established (Figs. 1A-1C) and shown to maintain expression of key pluripotency markers Oct4 and Nanog (Figs. 1D-1E), with stable pluripotency gene expression and consistent population doubling times over long-term culture (Fig. 2). Transitioning to 3D culture, fish ESCs were maintained as aggregates or as single cells under optimized conditions (Fig.3). Robust adipogenic differentiation was achieved in both 2D (Fig. 4) and 3D cultures (Fig. 5), as evidenced by lipid droplet accumulation and Bodipy staining. Similarly, myogenic differentiation was demonstrated by the formation of elongated myocyte-like cells, expression of musclespecific proteins SMA and Myh11, and upregulation of myogenic genes in both 2D (Fig. 6) and 3D (Fig. 7) systems. These results establish a foundational platform for the scalable production of fish-derived cell types.EXAMPLE 22D culture duration and passage requirements

[0127] The current data indicates that specific 2D culture durations are a prerequisite for successful 3D adaptation. Failure to meet these timelines results in adaptation failure.

[0128] Specifically, cells maintained in 2D culture for a period of 10.5 to 22.5 days (Passages 7–15) consistently failed to adapt (n=10).

[0129] In sharp contrast, cells maintained in 2D culture for a period of 76.5 to 150 days (Passages 51–100) successfully transitioned to 3D (n=6).EXAMPLE 3Temperature sensitivity

[0130] Temperature remains a critical factor. In that regard, the state of the art is conclusive of adequate temperature being required for successful growth. For example, Vergas-Castillo et al., 2021 [Comparative Biochemistry and Physiology, Part B], Walsh et al., 2024 [Current Research in Food Science], Yee Ho et al., 2014 [Zebrafish], Tan et al., 2023 [Animals], and Parameswaran et al., 2012 [Differentiation], reported successful growth at 22 °C, 23 °C, 26 °C, 28 °C, and 28.5°C. Nevertheless, these publications, and specifically Vergas-Castillo et al., reported failed growth at 13 °C, and declined growth / survival at 31 °C from day 10 onwards.

[0131] In sharp contrast, it is reported herein that successful adaptations (e.g., from 2D to 3D) occurred at 26 °C, 36 °C, and 37 °C. Adaptations attempted at 22 °C, 24 °C, 30 °C, and 32 °C were found to be unsuccessful.

[0132] While certain features of the invention have been illustrated and described herein, many modifications, substitutions, changes, and equivalents will now occur to those of ordinary skill in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the true spirit of the invention.

Claims

CLAIMSWhat is claimed is:

1. A method for maintaining pluripotency of a marine embryonic stem cell in a culture, the method comprising:a. isolating an embryonic stem cell from an embryo of a marine organism;andb. culturing said isolated embryonic stem cell from step (a) in a cell culture medium comprising: (i) a basal medium; and (ii) serum or a serum replacement, wherein said culturing is culturing in 2D followed by culturing in 3Dthereby, maintaining pluripotency of the marine embryonic stem cell in a culture.

2. The method of claim 1, wherein said cell culture medium further comprises any one of: basic fibroblast growth factor (bFGF), IL-6 / IL-6Ra chimera, epidermal growth factor (EGF), a non-essential amino acid or a plurality thereof, an antibiotic agent, and any combination thereof.

3. The method of claim 1 or 2, wherein said basal medium is any one of: L-15, DMEM, F12, and a combination thereof.

4. The method of any one of claims 1 to 3, wherein said culturing in 2D is for a period of between 50 and 200 days.

5. The method of any one of claims 1 to 4, wherein said culturing in 3D is for a period of between 1 and 60 days.

6. The method of any one of claims 1 to 5, wherein said culturing in 3D is solid support-free culturing.

7. The method of any one of claims 1 to 6, wherein said cells cultured in 3D are in the form of cell aggregates, single solitary cells, or a combination thereof.

8. The method of any one of claims 1 to 7, further comprising a step after step (b) comprising differentiating said cultured isolated embryonic cell in a pluripotent state, into a target cell type.

9. The method of claim 8, wherein the target cell type is an adipocyte, a myocyte, or a combination thereof.

10. The method of claim 8 or 9, wherein said differentiating comprises contacting said cultured isolated embryonic cell in a pluripotent state with an effective amount of a differentiation agent comprising: insulin, oleic acid, retinoic acid, or any combination thereof.

11. The method of claim 10, wherein said target cell is an adipocyte, and wherein said differentiation agent is an adipogenesis inducing agent comprising: insulin, oleic acid, or both.

12. The method of claim 11, wherein said target adipocyte comprises omega 3 fatty acid in an increased amount compared to a control cell.

13. The method of claim 12, wherein said differentiating further comprises subjecting the contacted cultured isolated embryonic cell to a temperature ranging between any one of: 25 °C and 27 °C, and 34 °C and 38 °C.

14. The method of claim 9, wherein said target cell is a myocyte, and wherein said differentiation agent is a myogenesis inducing agent comprising retinoic acid.

15. The method of any one of claims 1 to 14, wherein said marine organism is a fish.

16. The method of any one of claims 1 to 15, wherein said serum is fetal bovine serum, fish serum, or a combination thereof.

17. The method of any one of claims 1 to 16, wherein said cell culture medium has an osmolarity of 300-400 mOsm / kg.

18. A method for differentiating a marine embryonic pluripotent stem cell in a culture into an adipocyte cell, the method comprising contacting said marine embryonic pluripotent stem cell with an effective amount of a differentiation agent comprising: insulin, oleic acid, or both.

19. A method for differentiating a marine embryonic pluripotent stem cell in a culture into a myocyte cell, the method comprising contacting said marine embryonic pluripotent stem cell with an effective amount of a differentiation agent comprising retinoic acid.

20. The method of claim 18 or 19, wherein said marine embryonic pluripotent stem cell is in a suspension.

21. The method of claim 20, wherein said marine embryonic pluripotent stem cell is not adhered to a solid support in said suspension.

22. The method of any one of claims 18 to 21, wherein said marine organism is a fish.

23. A composition comprising a suspension of fish embryonic stem cells, wherein said fish stem cells are not in the form of embryoid body.

24. A composition comprising a suspension of fish adipocyte cells, wherein said fish adipocyte cells are present in said suspension in the form of aggregates, solitary cells, or a combination thereof.

25. The composition of claim 24, wherein each aggregate of said aggregates comprises between 50 to 1,000 fish adipocyte cells.

26. A composition comprising a suspension of fish myocyte cells, wherein said fish myocyte cells are present in said suspension in the form of: solitary cells, aggregates, or a combination thereof.

27. The composition of claim 26, wherein each aggregate of said aggregates comprises between 2 to 1,000 fish myocyte cells.

28. The composition of any one of claims 23 to 27, wherein said cells in said suspension are not adhered to a solid support.

29. The composition of any one of claims 23 to 28, further comprising an edible carrier.

30. The composition of any one of claims 23 to 29, being an edible composition.

31. The composition of any one of claims 23 to 30, being a food product or an ingredient thereof.